Trial Profile
Comparison of the human TNF-alpha antibody adalimumab with infliximab in induction and maintenance of steroid-free remission in patients with moderate to severe Crohn's disease.
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 31 Jul 2011
Price :
$35
*
At a glance
- Drugs Adalimumab (Primary) ; Infliximab (Primary)
- Indications Crohn's disease
- Focus Therapeutic Use
- Acronyms CHAMP
- 31 Jul 2011 New trial record